Global Schizophrenia Therapeutics Market Size, Status and Forecast 2019-2025

Published On: Jun 2019

Format: PDF

Publisher: QY Research

Pages: 92

Report ID: 1613

Schizophrenia therapeutics are used as a standard treatment regimen for schizophrenia. It helps in reversing the low levels of dopamine and serotonin, thereby improving the patient's condition.
The second-generation antipsychotic drugs segment accounted for the majority market shares because these drugs involve less side effects in comparison to their predecessors. The second-generation antipsychotic drugs are also called as atypical antipsychotic drugs. The increased efficacy and reduced side effects of these drugs improves the negative symptoms, decreases extrapyramidal side-effects (EPSE), and normalizes the level of prolactin. The improvement in negative and cognitive symptoms and the reduction in occurrences of EPSE is attributed to their antagonizing action on serotonin or 5-HT2A receptors. This in turn, will boost the segment’s growth throughout the estimated period.
In 2018, the global Schizophrenia Therapeutics market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Schizophrenia Therapeutics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Schizophrenia Therapeutics development in United States, Europe and China.

The key players covered in this study
AstraZeneca
Eli Lilly
GlaxoSmithKline
Johnson & Johnson
Alkermes
AbbVie
Amgen
Bristol-Myers Squibb

Market segment by Type, the product can be split into
First-Generation Antipsychotic Drugs
Second-Generation Antipsychotic Drugs
Third-Generation Antipsychotic Drugs

Market segment by Application, split into
Hospitals
Clinics
Other

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Schizophrenia Therapeutics status, future forecast, growth opportunity, key market and key players.
To present the Schizophrenia Therapeutics development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Schizophrenia Therapeutics are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Schizophrenia Therapeutics Market Size Growth Rate by Type (2014-2025)
1.4.2 First-Generation Antipsychotic Drugs
1.4.3 Second-Generation Antipsychotic Drugs
1.4.4 Third-Generation Antipsychotic Drugs
1.5 Market by Application
1.5.1 Global Schizophrenia Therapeutics Market Share by Application (2014-2025)
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Other
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Schizophrenia Therapeutics Market Size
2.2 Schizophrenia Therapeutics Growth Trends by Regions
2.2.1 Schizophrenia Therapeutics Market Size by Regions (2014-2025)
2.2.2 Schizophrenia Therapeutics Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities

3 Market Share by Key Players
3.1 Schizophrenia Therapeutics Market Size by Manufacturers
3.1.1 Global Schizophrenia Therapeutics Revenue by Manufacturers (2014-2019)
3.1.2 Global Schizophrenia Therapeutics Revenue Market Share by Manufacturers (2014-2019)
3.1.3 Global Schizophrenia Therapeutics Market Concentration Ratio (CR5 and HHI)
3.2 Schizophrenia Therapeutics Key Players Head office and Area Served
3.3 Key Players Schizophrenia Therapeutics Product/Solution/Service
3.4 Date of Enter into Schizophrenia Therapeutics Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global Schizophrenia Therapeutics Market Size by Type (2014-2019)
4.2 Global Schizophrenia Therapeutics Market Size by Application (2014-2019)

5 United States
5.1 United States Schizophrenia Therapeutics Market Size (2014-2019)
5.2 Schizophrenia Therapeutics Key Players in United States
5.3 United States Schizophrenia Therapeutics Market Size by Type
5.4 United States Schizophrenia Therapeutics Market Size by Application

6 Europe
6.1 Europe Schizophrenia Therapeutics Market Size (2014-2019)
6.2 Schizophrenia Therapeutics Key Players in Europe
6.3 Europe Schizophrenia Therapeutics Market Size by Type
6.4 Europe Schizophrenia Therapeutics Market Size by Application

7 China
7.1 China Schizophrenia Therapeutics Market Size (2014-2019)
7.2 Schizophrenia Therapeutics Key Players in China
7.3 China Schizophrenia Therapeutics Market Size by Type
7.4 China Schizophrenia Therapeutics Market Size by Application

8 Japan
8.1 Japan Schizophrenia Therapeutics Market Size (2014-2019)
8.2 Schizophrenia Therapeutics Key Players in Japan
8.3 Japan Schizophrenia Therapeutics Market Size by Type
8.4 Japan Schizophrenia Therapeutics Market Size by Application

9 Southeast Asia
9.1 Southeast Asia Schizophrenia Therapeutics Market Size (2014-2019)
9.2 Schizophrenia Therapeutics Key Players in Southeast Asia
9.3 Southeast Asia Schizophrenia Therapeutics Market Size by Type
9.4 Southeast Asia Schizophrenia Therapeutics Market Size by Application

10 India
10.1 India Schizophrenia Therapeutics Market Size (2014-2019)
10.2 Schizophrenia Therapeutics Key Players in India
10.3 India Schizophrenia Therapeutics Market Size by Type
10.4 India Schizophrenia Therapeutics Market Size by Application

11 Central & South America
11.1 Central & South America Schizophrenia Therapeutics Market Size (2014-2019)
11.2 Schizophrenia Therapeutics Key Players in Central & South America
11.3 Central & South America Schizophrenia Therapeutics Market Size by Type
11.4 Central & South America Schizophrenia Therapeutics Market Size by Application

12 International Players Profiles
12.1 AstraZeneca
12.1.1 AstraZeneca Company Details
12.1.2 Company Description and Business Overview
12.1.3 Schizophrenia Therapeutics Introduction
12.1.4 AstraZeneca Revenue in Schizophrenia Therapeutics Business (2014-2019)
12.1.5 AstraZeneca Recent Development
12.2 Eli Lilly
12.2.1 Eli Lilly Company Details
12.2.2 Company Description and Business Overview
12.2.3 Schizophrenia Therapeutics Introduction
12.2.4 Eli Lilly Revenue in Schizophrenia Therapeutics Business (2014-2019)
12.2.5 Eli Lilly Recent Development
12.3 GlaxoSmithKline
12.3.1 GlaxoSmithKline Company Details
12.3.2 Company Description and Business Overview
12.3.3 Schizophrenia Therapeutics Introduction
12.3.4 GlaxoSmithKline Revenue in Schizophrenia Therapeutics Business (2014-2019)
12.3.5 GlaxoSmithKline Recent Development
12.4 Johnson & Johnson
12.4.1 Johnson & Johnson Company Details
12.4.2 Company Description and Business Overview
12.4.3 Schizophrenia Therapeutics Introduction
12.4.4 Johnson & Johnson Revenue in Schizophrenia Therapeutics Business (2014-2019)
12.4.5 Johnson & Johnson Recent Development
12.5 Alkermes
12.5.1 Alkermes Company Details
12.5.2 Company Description and Business Overview
12.5.3 Schizophrenia Therapeutics Introduction
12.5.4 Alkermes Revenue in Schizophrenia Therapeutics Business (2014-2019)
12.5.5 Alkermes Recent Development
12.6 AbbVie
12.6.1 AbbVie Company Details
12.6.2 Company Description and Business Overview
12.6.3 Schizophrenia Therapeutics Introduction
12.6.4 AbbVie Revenue in Schizophrenia Therapeutics Business (2014-2019)
12.6.5 AbbVie Recent Development
12.7 Amgen
12.7.1 Amgen Company Details
12.7.2 Company Description and Business Overview
12.7.3 Schizophrenia Therapeutics Introduction
12.7.4 Amgen Revenue in Schizophrenia Therapeutics Business (2014-2019)
12.7.5 Amgen Recent Development
12.8 Bristol-Myers Squibb
12.8.1 Bristol-Myers Squibb Company Details
12.8.2 Company Description and Business Overview
12.8.3 Schizophrenia Therapeutics Introduction
12.8.4 Bristol-Myers Squibb Revenue in Schizophrenia Therapeutics Business (2014-2019)
12.8.5 Bristol-Myers Squibb Recent Development

13 Market Forecast 2019-2025
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2019-2025)
13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details